BarbriSFCourseDetails
  • videocam Live Online with Live Q&A
  • calendar_month December 17, 2025 @ 1:00 p.m. ET./10:00 a.m. PT
  • signal_cellular_alt Intermediate
  • card_travel Health
  • schedule 90 minutes

ACOs, Clinically Integrated Networks, and Super CINs: Must Know Emerging Legal and Regulatory Developments for Non-Profit, For Profit and Private Equity Backed Participants

Early Bird Pricing!
MSRP
$297.00
$252.45
Save $44.55

Discount expires 12/5/25

This course is $0 with these passes:

CLE
ALL
  1. keyboard_arrow_leftBack
BarbriPdBannerMessage

About the Course

Introduction

This CLE course will provide an overview of "must know" legal, regulatory, and case law developments that are important to the future formation and operation of hospital and physician clinically integrated networks (CINs) and Accountable Care Organizations (ACOs). The topics will include recent regulatory activity, court actions and emerging issues of federal and state antitrust law, healthcare fraud, waste and abuse laws, information privacy and data sharing regulations, corporate practice of medicine and fee splitting restrictions, and state and federal tax law. Understanding these emerging issues can help providers ensure that their participation in value-based care is a sound and productive venture that advances the work of providers to meet community and stakeholder needs. The course will provide an opportunity for Q&A to allow listeners to focus the discussion on what is most relevant to them.

Description

Recent market shifts and a variety of federal and state incentives make participation in ACOs and CINS a potential option for hospital and physician providers to collaborate, manage costs and improve quality and efficiency in healthcare delivery. 

Against this backdrop, several recent large CIN and ACO transactions (including creation of “Super-CINs”), litigation matters, and regulatory and statutory changes provide an important roadmap for providers participating in or considering such collaborations to optimize benefit.

Listen as our authoritative panel of experts provides an in-depth discussion of new and emerging legal and regulatory considerations that may impact the landscape for hospitals, physicians and payors as they consider or advance their participation in or oversight of a CIN or ACO. 

Presented By

Andrea Ferrari
Senior Counsel
Hancock Daniel & Johnson PC

Ms. Ferrari is a member of Hancock Daniel’s corporate healthcare group, where she focuses on issues related to transactional and enterprise compensation planning, governance and review, particularly issues related to fair market value and commercial reasonableness. Although her past experience encompasses a multitude of regulatory, transactional, governance and investigation matters, Ms. Ferrari is known especially for her work in recruitment and retention of highly compensated thought leader physicians and executives; and incentive payment distributions through ACOs and clinically integrated networks to advance value-based care initiatives. She has worked extensively with clients navigating the intersection of regulatory and financial considerations in clinical research, including agreements for funding and support services and the related issues of contracting and compliance; transactional due diligence for compensation compliance; and navigating the intersection of compensation and antitrust issues. Ms. Ferrari's expertise also includes recruitment, compensation and procurement governance for “essential” hospitals such as public, rural, academic and pediatric hospitals.

expand_circle_down Expand to View Full Bio expand_circle_up Collapse Bio
Credit Information

  • This 90-minute webinar is eligible in most states for 1.5 CLE credits.


  • Live Online


    On Demand

Date + Time

  • event

    Wednesday, December 17, 2025

  • schedule

    1:00 p.m. ET./10:00 a.m. PT

I. Overview of selected key recent and proposed changes and case law developments in federal and state antitrust law; healthcare fraud, waste and abuse laws; payor regulations; information privacy and data sharing; state licensing and fiduciary requirements; corporate practice of medicine restrictions; and state and federal non-profit and for-profit tax law

II. Current and future organizational and governance issues in the evolving regulatory environment, including issues related to monitoring and maximizing participant financial incentives while ensuring compliant, fair market value and commercially reasonable payments

III. What can be learned from recent case law and examples in the market

IV. Suggestions for best practices going forward, including for information tracking and sharing, management and governance, and payments of incentives and distributions

The panel will review these and other key issues:

  • Regulatory compliance and due diligence questions CINs and ACOs face under the emerging federal and state legal and regulatory landscape, including fraud, waste and abuse laws; antitrust; corporate practice of medicine; fee splitting; tax exemption laws and regulations; and emerging issues for corporate fiduciaries.
  • Factors healthcare providers, non-profit and corporate sponsors, and their counsel should consider when selecting and managing value-based population health incentive programs in 2025/2026.
  • When and why contributions to and payments from a CIN should be evaluated for fair market value and reasonableness.
  • Special considerations when CIN participants enter or leave a network, are hospital-employed physicians, not-for-profit entities, and/or private equity investors.